anthonyyazdaniml/gliner-biomed-balanced-curated-corpus huggingface dataset:
Products containing vitamin A and/or vitamin D which are stable in admixture with mineral preparations and mixtures of mineral preparations and protein concentrates are made by adding to a vitamin A and/or vitamin D material at least 2g. of 4-methyl-2,6-ditertiary-butylphenol per 100 Standard Units of vitamin A and/or vitamin D, dispersing this mixture in liquid or molten state in an aqueous liquid containing a jellifiable, film-forming colloid, and converting the dispersion to small, dry particles, e.g., by dispersing the dispersion in warm castor oil or paraffin oil, cooling to produce particles, and dissolving off the oil by hexane, acetone, ethanol, isopropanol, methyl ethyl ketone or n-propanol, or by spraying the dispersion into a hot chamber.  The colloids are exemplified by gelatine, blood albumen, lactalbumin, carboxymethylcellulose, methyl cellulose, starch and hydrolyzed starch.  The dispersion preferably contains a carbohydrate such as lactose, glucose or maltose.  A mineral mixture of calcium carbonate, steamed bone meal, dicalcium phosphate, iodized sodium chloride, magnesium, ferrous, copper, manganese and cobalt sulphates and a protein concentrate of soybean, fish, blood and sunflower seed meals are referred to.ALSO:A method of producing a dry, free-flowing mineral stable Vitamin A and/or D preparation comprises adding to a Vitamin A and/or D phase at least 2 gm. of 4-methyl-2,6-ditertiary-butyl phenol per 100 Standard Units (i.e. 108 International Units) of Vitamin A and/or D, dispersing this mixture in a liquid or molten state in an aqueous liquid containing a jellifiable film-forming colloid and working up this aqueous emulsion to obtain small dry particles.  These particles may be produced by dispersing the aqueous emulsion in an oil such as castor or paraffin oil while warm and cooling to produce discrete particles after which the oil is removed by a suitable solvent, e.g. hexane, acetone, ethanol, isopropanol, methylethyl ketone or n-propanol. Alternatively the particles may be produced by spraying the emulsion into a hot air chamber.  The film-forming colloids used may be proteins, e.g. gelatine, blood albumen, or lactalbumin, carboxymethylcellulose, methylcellulose or starch.  Preferably the aqueous emulsion contains also one or more carbohydrates, e.g. lactose, glucose or maltose.  A &#34;mineral stable preparation&#34; is defined as being one which, having been mixed with mineral mixtures or protein concentrates in dilutions of 1 to 1000 or more, and being kept at room temperature in an atmosphere of at least 55 per cent relative humidity will have a vitamin content of at least 70 per cent of the initial vitamin content after a six months&#39; storage period.  The dry preparations may be made up into pills or tablets or mixed with food preparations.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a method for producing granulated particles capable of stably holding a chemically unstable bioactive substance over a long period by a simple and highly safe method.  &lt;P&gt;SOLUTION: The method for producing the granulated particles by charging additive particles into a jetting fluidized bed granulation apparatus, and spraying a liquid obtained by formulating an aqueous solution of a stabilizer, a binder and the bioactive substance particles while keeping the fluidized state, includes adding 2-18 pts.wt. of the stabilizer, the binder and the bioactive substance particles dissolved or suspended in water to 1 pt.wt. of the additive particles charged to the jetting fluidized bed apparatus and spray it to produce the granulated particles. A high-quality tablet rapidly disintegrable in the oral cavity can be produced by using the granulated particles produced by the method.  &lt;P&gt;COPYRIGHT: (C)2011,JPO&amp;INPIT
Application of a virus with poloxamer alone onto atria results in diffuse epicardial gene transfer with negligible penetration into the myocardium. Progressive increases in protease concentration, however, allow transmural gene transfer. After protease exposure, echocardiographic left atrial diameter does not change. Left atrial ejection fraction decreases on post-operative day 3, but returns to baseline by day 7. At appropriate protease concentrations, tissue tensile strength is unaffected by the procedure. Transmural atrial gene transfer can be effected using this direct &#39;painting&#39; method.
A method and system for use in treating a patient receiving an anticoagulant or a substance containing warfarin to optimize therapy and prevent an adverse drug response. The system performs the steps shown in blocks (10, 12) of the flow chart. The system employs surrogate markers or indicators including blood levels of the anticoagulant to determine the next required dose for a patient. Because the surrogate markers are employed as a percent change in status, virtually any indicator can be used. Surrogate markers could include any measure of effectiveness of the anticoagulant&#39;s action. Given the effectiveness of the anticoagulant&#39;s action relative to the surrogate markers, a change in anticoagulant dose is calculated by the system. Conversely, by employing this system, one could determine the expected result of the anticoagulant dose change on the surrogate markers.
&lt;P&gt;PROBLEM TO BE SOLVED: To develop and apply a new cosmetic composition having high bleaching effect or skin antiaging effect.  &lt;P&gt;SOLUTION: This cosmetic composition comprises (A) one or more kinds of squaric acid or salt(s) thereof and (B) one or more organic acids. A 2nd version of this cosmetic composition comprises the components A and B and also (C) a polyhydric alcohol or fatty acid ester. The 1st version of this composition has melanogenesis inhibitory activity, antioxidative activity, collagen production promoting activity, MMP( collagenase or elastase ) production inhibitory activity and skin resiliency improving effect, therefore having significant bleaching effect and skin antiaging effect. The 2nd version of this composition has the effects of preventing skin irritation and rough skin.  &lt;P&gt;COPYRIGHT: (C)2005,JPO&amp;NCIPI
The invention provides methods and apparatus for stable generation and delivery of solid nano-particles in aerosols that simultaneously maintain high nano-particle concentration, and which avoid coagulation and agglomeration of the nano-particles. The apparatus includes a Collison nebulizer is in communication with a plenum. The Collison nebulizer includes a port for introducing a helium gas flow into the Collison nebulizer. The plenum includes component(s) for providing flow of uniform axially symmetrical dry air around the nano-particles entrained in the helium gas flow in the plenum. Preferably, the plenum includes an uniformity screen and a reduction in the plenum circumference downstream from the uniformity screen. In some preferred aspects, the invention provides methods of introducing nanoparticles into the lungs of test animals. The present invention allows more than 0.5 mass % of the nano-particles to be deposited in an animal&#39;s lungs.
The present invention relates generally to methods of inhibiting the onset and progression of Alzheimer&#39;s disease (AD), mild cognitive impairment (MCI), and related neurodegenerative disorders involving amyloidosis. The methods involve administering a composition comprising a therapeutically effective amount of D-pinitol to individuals who are at risk of developing the disease or have one or more symptoms of the disease. The invention also relates to methods of treating or preventing Alzheimer&#39;s disease or MCI that involve the use of such compositions. The invention further provides methods to promote the general health of the nervous system through administration of active ingredient compositions. The invention further relates to animal and cellular systems for the study of AD, MCI, and related disorders, and the identification of reagents useful in treating amyloidosis. The invention further provides methods to inhibit AD or MCI in an individual based on reducing caloric intake by the individual. The invention further relates to a method of treating or inhibiting an amyloidogenic disorder by caloric restriction.
Tooth pastes comprise sodium perborate, liquid petrolatum, a body-supplying component, and an emulsifying-agent consisting of soap or sodium lauryl sulphate or sodium cetyl sulphate, and, preferably, a higher alcohol such as cetyl or lauryl alcohol.  The body-supplying component may be colloidal kaolin or ceresin or mixtures of these or bentonite, magnesium stearate, magnesium carbonate, calcium sulphate, calcium phosphate, or fuller&#39;s earth.ALSO:Tooth pastes comprise sodium perborate, liquid petrolatum, a body-supplying component such as colloidal kaolin or ceresin or both, an emulsifying-agent consisting of powdered soap or sodium lauryl sulphate or sodium cetyl sulphate, and preferably a higher p  alcohol such as cetyl or lauryl alcohol.  The perborate used may be the tetrahydrate or the monohydrate.  The ingredients are mixed in the cold state, or, when ceresin is used, the heated mixture is cooled before the perborate is added.  The liquid petrolatum used may vary in specific gravity between 0,778 and 0,89. Colloidal kaolin may be replaced by bentonite, magnesium stearate, magnesium carbonate, calcium sulphate, calcium phosphate or fuller&#39;s earth.  A mixture of saccharin and oil of wintergreen may be used as a flavouring.  Mixtures of sodium perborate with petroleum jelly are also referred to.
The present invention discloses a kind of antistress function additive that reduces the cavy death rate and its preparation method and application. The each composition weight proportioning of this additive is&lt;b&gt;:&lt;/b&gt;NaCl? 1-5 part, KCl? 1-5 part, glucose 1-15 part, sodium bicarbonate 1-6 part, vitamin C? 1-5 part, B family vitamin 1-5 part. 1500 times of purified water dilutions for this compositions of additives, respectively cavy transport first 1 day and transport arrive new environment after 3 days, freely drink. On normal diet basis, add and feed appropriate compositions of additives of the present invention, to supplement sufficient vitamin and electrolyte, reduce the stress reaction of cavy, be conducive to the adaptation of cavy to environment and the demand of nutrition, not only cavy body weight is had to remarkable increase, and greatly reduce the cavy death rate and sufferer rate.
FIELD: medicine. ^ SUBSTANCE: invention refers to medicine, specifically to dermatology, and can be used for treating the patients suffering eczema. The method involves comprehensive drug therapy including administration of antihistamines and glucocorticosteroids, and also prescription of Cytoflavinum orally 2 tablets twice a day 30 minutes before meals. In the evening, the drug is taken not later than 18 o&#39;clock. Length of the therapeutic course is 25 days. ^ EFFECT: method enables higher clinical effectiveness in the patients suffering eczema due to relief of core symptoms of eczema and correction principal pathogenic mechanisms of said pathology, and also faster regression of clinical presentation, improved endotoxicosis values, immunological values, stimulated antioxidant protection and albumin status factors. ^ 1 dwg, 17 tbl
Cognitive behavioral therapy and mindfulness-based therapies are successful practices in reducing anxiety and psychological distress (Ghielen et al. 2019). Mindfulness training includes teaching a range of meditation techniques as well as how to focus on the present moment in daily activities (Monshat, K., \&amp; Castle, D. J., 2012). Mindfulness training given to patients undergoing hip replacement surgery has been shown to reduce postoperative pain and improve their physical functioning (Dowsey et al., 2019). Similarly, it has been reported that mindfulness training given to patients who will undergo knee and hip replacement before surgery can prevent postoperative pain and opioid use (Hanley et al., 2021). In a study, mindfulness training used in the management of pain after lumbar disc herniation surgery was found to be useful in managing postoperative pain (Juneyoung et al., 2019). Aromatherapy with lavender oil was found to be effective in reducing pain after inguinal hernia surgery (Bagheri et al., 2020). This suggests that in addition to pharmacological pain management, non-pharmacological methods are also effective in pain management and can be used. In a meta-analysis evaluating the effectiveness of mindfulness-based interventions in acute pain, it was found that there was a lack of good quality evidence for the effectiveness of mindfulness-based interventions in reducing pain severity in clinical or experimental settings (Shires et al., 2020). It is stated that more rigorous large-scale studies conducted with pain populations are needed before cognitive behavioral therapies can be definitively recommended as first-line treatment for acute or chronic pain (McClintock et al., 2021). Therefore, our study was planned to determine the effect of preoperative awareness training on postoperative pain in patients undergoing inguinal hernia repair surgery.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a new type mutation for achieving selective duplication of tumor cells having sure genetic deficiency different from p53 and RB routes.  &lt;P&gt;SOLUTION: There is provided use of an adenovirus for cancer treatment, which adenovirus is defective in its virus-associated (VA) RNAs. The adenovirus has a mutation in the VAI or VAII gene sequence or both. The adenovirus may also have mutations in the sequences controlling expression of the VA RNAs. The adenovirus is injected into tumor, a cavity where the tumor is localized, or a bloodstream of a patient. The adenovirus is used together with another treatment mode such as chemotherapy and radiotherapy.  &lt;P&gt;COPYRIGHT: (C)2010,JPO&amp;INPIT
The present disclosure relates to &#34;managing user information&#34;. The invention provides a system, method and computer-readable medium for managing user information. For example, the user&#39;s data may be stored in memory. A request may be provided for a user to authorize access to at least a portion of the data. The authorization may be used to enable an application to access a portion of the data. In some examples, a response to the request may be received and an indication that the request was provided to the user may be provided without indicating whether the user denied the request.
PURPOSE:To provide a solid drug containing disodium adenosine triphosphate (ATP-2Na) and a vitamin B1 derivative, having promoted drug action of ATP-2 Na and useful for the amelioration and remedy of cerebrovascular disorder, cardiac insufficiency and asthenopia. CONSTITUTION:The objective drug contains ATP-2Na and a vitamin B1 salt or a vitamin B1 derivative having vitamin B1 activity (e.g., fursultiamine or its salt). The amount of the vitamin B1 is 0.01-5pts.wt., preferably 0.1-1pt.wt. per 1pt.wt. of ATP-2Na. The decomposition of ATP-2Na can be remarkably suppressed and a drug preparation having higher stability and effectiveness can be prepared by adding &gt;=0.1pts.wt. of a low-melting oily substance. The amount of the oily substance is preferably 0.2-1pt.wt. in the case of adding as a solid and 0.2-0.8pts.wt. as a liquid.
&lt;P&gt;PROBLEM TO BE SOLVED: To support efficient image reading by diagnostic image data without requiring special administrators and dedicated terminals for medical image diagnosis work.  &lt;P&gt;SOLUTION: A medical image diagnosis management apparatus 210 comprises a DICOM Web server 211, an order server 212 and a report server 213. The DICOM Web server 211 receives DICOM data sent thereto and stores and manages them in an image database 214. The order server 212 creates and manages an order list 215 as the base of order management. The report server 213 presents a report creation screen to each diagnostic terminal 220 to create and manage a report database 216, and upon report completion, outputs an image reading report to a printer 240 or the like. The DICOM Web server 211 stores a viewer 221 for displaying DICOM image data on the diagnostic terminal 220 and downloads the viewer in advance.  &lt;P&gt;COPYRIGHT: (C)2006,JPO&amp;NCIPI
PURPOSE:To provide a dentifrice composition having excellent light resistance, and resistant to discoloration even in a container having a transparent part to enable the transmission of sun light, by coloring a dentifrice with a heat-resistant tar pigment and filling the dentifrice in a container having a transparent part. CONSTITUTION:A colored dentifrice composition colored with a light-resistant tar pigment such as Food Red 106, Food Red 2, Food Yellow 4, etc., and filled in a transparent container. At least a part of the container has a visible light transmittance of &gt;=50%. When a filler (preferably titanium dioxide) is added to the above composition in an amount of 0.001-5wt% of the whole composition, the light resistance can be improved remarkably without lowering the beautiful appearance of the dentifrice, and the containing composition can be filled suitably in a transparent container having a clear part with an ultraviolet transmittance of as high as &gt;=5%. Even a transparent container wherein the ultraviolet transmission of the transparent container wherein the ultraviolet transmission of the transparent part is &gt;=3% may be used effectively, however, it is preferable to keep the transmittance to &lt;=30% to prevent the discoloration of the perfumery, binder, etc. of the dentifrice composition.
PROBLEM TO BE SOLVED: To treat infantile hyperstellar cell tumors including brain stem nerve gliocystoma by administrating temozolomide. SOLUTION: Temozolomide of the formula (namely, 3,4-dihydro-3- methyl-4-oxoimidazo-[50,1-d] 1,2,3,4-tetrazine-8-carboximide) is administered. Preferably, the total dose of 50-1,200mg per 1m&lt;2&gt; body surface area of a patient is administered continuously during 5 days. In the case of the total dose 1,000mg/m&lt;2&gt; , a daily dose of 200mg/m&lt;2&gt; is preferably administered for 5 days. Preferably, after a period of 28 days from the first day of the administration temozolomide is repeatedly administered. Otherwise, a smaller amount of dose is administered for a longer period. Preferably, a dose of 75mg/m&lt;2&gt; is administered for 6 to 7 weeks. temozolomide is mixed with anhydrous lactose NF, starch sodium glycolate NF, colloidal silicon dioxide NF, tartaric acid NF and stearic acid NF and can be administered in the form of capsule.
PURPOSE:To obtain a preparation for central vein administration, containing glucose and amino acids. CONSTITUTION:A solution (the first solution) containing glucose is isolated from a solution (the second solution) containing amino acids. A desired amount of branched-chain amino acids (&gt;=40wt.% branched-chain amino acids) is divided into suitable amounts of two portions and dissolved respectively in the glucose- containing solution (the first solution) and the amino acid-containing solution (the second solution). Both the solutions are mixed before use. In this preparation for central vein administration, branched-chain amino acids are contained in a high concentration of &gt;=40wt.% and coloration due to decomposition of glucose can be prevented. This preparation has an improved shelf life.
The present invention provides a &#39; infantile eczema eliminating agent &#39; which is a drug for treating infantile eczema, and a preparing method thereof. Chinese drugs, such as medical stone, etc. and western drugs, such as diphenhydramine, etc. are organically combined on the basis of Chinese traditional medicine. The drug for treating infantile eczema contains various microelements without hormone, and has the advantages of quick effect, no side effect, etc. The clinical total effective rate achieves 98%. The preparation method comprises: after Chinese drugs and western drugs are ground into fine powder, the fine powder and a cream base material are mixed. The present invention is the successful try of creating a new drug by the integration of Chinese traditional medicine and western medicine.
The specification comprises 2,5,6 tricarbalcoxy-L-ascorbic acid esters of the formula:  &lt;FORM:0869458/IV (b)/1&gt; where R2 is an alkyl group containing from 1 to 3 carbon atoms.  Specified esters are 2,5,6 tricarbmethoxy-L-ascorbic acid ester and the corresponding ethoxy and propoxy esters.  These esters may be made by esterifying L-ascorbic acid or a salt thereof, or a derivative in which instead of the free OH groups present in the 5 and 6 positions these are replaced by organic or inorganic radicals which are capable of being easily hydrolysed to OH groups, such as the isopropylidene group, with alkyl esters of chloro- or bromocarbonic acid under alkaline conditions.  These conditions may be obtained by means of organic tertiary bases such as pyridine, lutidine or collidine.  In examples, 2,5,6tricarbethoxy-L-ascorbic acid ester is obtained by adding chlorocarbonic acid ethyl ester dissolved in acetone slowly to ascorbic acid or 5,6 iso-propylidene L-ascorbic acid in pyridine at O to -5 DEG C. and stirring for 2 hours, HCI gas is then added and the oil formed is dissolved in chloroform and shaken out with saturated sodium hydrogen carbonate solution.  This solution is acidified with concs HCI and extracted with ether.  After removal of the ether the light yellow syrup crystallises.  These esters are relatively thermostable and may be used in foodstuffs such as bread.ALSO:2,5,6-Tricarbalkoxy-L-ascorbic acid esters of the formula &lt;FORM:0869458/VI/1&gt; where R2 is an alkyl group containing from 1 to 3 carbon atoms, are used as a source of Vitamin C in foodstuffs, in particular bread, as they lose only 10% of their Vitamin C activity during heat treatment, e.g. baking or sterilization processes. Specified esters are 2,5,6-tricarbmethoxy L-ascorbic acid ester and the corresponding ethoxy and propoxy esters, which esters may be made by the methods described in Group IV (b).
&lt;P&gt;PROBLEM TO BE SOLVED: To obtain a diabetes preventing and ameliorating agent having low risk of side actions and developing excellent effect.  &lt;P&gt;SOLUTION: A Hericium erinaceum strain has a deposition No. of FERM P-19600. The diabetes preventing and ameliorating agent contains the Hericium erinaceum as an active component. The diabetes preventing and ameliorating agent preferably contains dried powder and/or its hot-water extract of Hericium erinaceum. The Hericium erinaceum of the diabetes preventing and ameliorating agent is preferably the Hericium erinaceum strain having the deposition No. of FERM P-19600.  &lt;P&gt;COPYRIGHT: (C)2005,JPO&amp;NCIPI
A muscle injury prevention and muscle strengthening system has an electrode harness, a controller, electrical muscle stimulation (EMS) electrodes, and an environmental sensor. The electrode harness secures around the patient&#39;s body holding the EMS electrodes in contact with the patient&#39;s body. The EMS electrodes send targeted electrical pulses at the motor nerves of the patient. The environmental sensor observes responses from the patient while monitoring external environmental factors. The environmental sensors range from EMG sensors to location sensors to gather important information about the patient and the environment. The controller manages the operation of the electrical components of the present invention. The present invention is fastened securely to the patient throughout all exercises and activities to properly stimulate the patient and gather responses from the patient.